See What HealthDay Can Do For You
Contact Us

Vonvendi Approved to Control Bleeding Disorder

Clotting factor sanctioned for von Willebrand disease

TUESDAY, Dec. 8, 2015 (HealthDay News) -- Vonvendi has been approved to treat adults with von Willebrand disease (VWD), the most common inherited bleeding disorder.

VWD, affecting about 1 percent of the U.S. population, is caused by lack of a protein that's essential for blood clotting. People with the disorder can develop severe bleeding from the nose, gums, intestines, muscles and joints. Women with VWD also can bleed excessively after a menstrual period or after giving birth.

Vonvendi, a genetically engineered (recombinant) form of the missing protein, was evaluated in clinical studies of 69 adults with VWD. Itching was the most common side effect, the FDA said Tuesday in a news release.

Vonvendi is produced by Baxalta, based in Westlake Village, Calif.

More information

Visit the FDA to learn more.

Consumer News


HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.